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Abstract Patient preferences, convenience, and bone
turnover markers were evaluated for the monthly ibandr-
onate over the weekly risedronate regimen in Korean
postmenopausal osteoporotic women. This was a 6-month,
prospective, randomized, open-label, multicenter study
with a two-period and two-sequence crossover treatment
design. After a 30-day screening period, eligible
participants with postmenopausal osteoporosis were ran-
domized to receive either monthly oral ibandronate 150 mg
for 3 months followed by weekly oral risedronate 35 mg
for 12 weeks (sequence A) or the same regimen in reverse
order (sequence B). Patient preference and convenience
were evaluated by questionnaire. The changes in serum C-
telopeptide after 3 months of treatment were analyzed. A
total of 365 patients were enrolled in this study (sequence
A 182, sequence B 183). Of patients expressing a prefer-
ence (83.4%), 74.8% preferred the monthly ibandronateThis study was conducted as clinical trial of GSK Korea as protocol
number 109393.
Y.-S. Chung
Department of Endocrinology and Metabolism,
Ajou University School of Medicine, Suwon, Korea
S.-K. Lim (&)
Division of Endocrinology and Metabolism,
Department of Internal Medicine, Yonsei University College of
Medicine, 134 Shinchon-dong, Seodaemun-gu, Seoul 120-752,
South Korea
e-mail: lsk@yumc.yonsei.ac.kr
H.-Y. Chung
Division of Endocrinology and Metabolism,
Department of Internal Medicine, KyungHee University,
Seoul, Korea
I.-K. Lee
Department of Internal Medicine,
Kyungpook National University School of Medicine,
Daegu, Korea
I.-H. Park
Department of Orthopedic Surgery, Kyungpook National
University School of Medicine, Daegu, Korea
G.-S. Kim
Division of Endocrinology and Metabolism,
Department of Internal Medicine, Asan Medical Center,
Seoul, Korea
Y.-K. Min
Division of Endocrinology and Metabolism,
Department of Medicine, Samsung Medical Center,
Sungkyunkwan University School of Medicine, Seoul, Korea
M.-I. Kang
Division of Endocrinology and Metabolism,
Department of Internal Medicine, The Catholic University of
Korea, Seoul St. Mary’s Hospital, Seoul, Korea
D.-J. Chung
Division of Endocrinology and Metabolism,
Department of Internal Medicine,
Chonnam National University Medical School, Gwangju, Korea
Y.-K. Kim
Division of Endocrinology and Metabolism,
Department of Internal Medicine, Pusan National University
College of Medicine, Pusan, Korea
W. H. Choi
Division of Endocrinology and Metabolism,
Department of Internal Medicine, Hanyang University,
Seoul, Korea
M. H. Shong
Division of Endocrinology and Metabolism,
Department of Internal Medicine, ChungNam National
University, Daejeon, Korea
123
Calcif Tissue Int (2009) 85:389–397
DOI 10.1007/s00223-009-9294-y
regimen over the weekly regimen (25.2%). More women
stated that the monthly ibandronate regimen was more
convenient (84.2%) than the weekly regimen (15.8%).
There was no significant difference in the change in bone
turnover marker between the two treatments. The two
regimens were similarly tolerable. There were fewer
adverse events in the monthly ibandronate group compared
to the weekly risedronate group in terms of gastrointestinal
side effects (nausea and abdominal distension). This study
revealed a strong preference and convenience for monthly
ibandronate over weekly risedronate in Korean postmeno-
pausal osteoporotic women. There was no significant dif-
ference in change of bone turnover marker and safety
profile between the two regimens.
Keywords Ibandronate  Risedronate  Preference 
Convenience  Korean
With the progressive aging of the world’s population,
osteoporosis has emerged as an important global health
problem. Based on population growth and the current
incidence of hip fractures in Asia, it is estimated that by
2050 50% of the world’s hip fractures will occur in Asian
women [1].
Bisphosphonates are regarded as the treatment of choice
for postmenopausal osteoporosis and have proven clinical
benefits, including a significantly reduced risk of vertebral
and nonvertebral fractures in many clinical trials [2–6].
However, adherence to treatment among patients with
postmenopausal osteoporosis is currently suboptimal, like
in other chronic diseases [7, 8]. Poor adherence leads to
reduced clinical benefit, a raised incidence of secondary
complications, and therefore increased health-care costs
[7]. Data from a study evaluating adherence to bis-
phosphonate therapy show that the probability of contin-
uing daily oral treatment is approximately 50% at 1 year
[9]. This problem is largely contributed to the complex and
inconvenient dosing instructions due to their low bio-
availability and the potential for upper gastrointestinal (GI)
side effects [8].
Patient treatment preference is an important factor in
determining patient satisfaction with medical care and could
provide an efficient way of maximizing the effectiveness of
medical care [10]. Patient preferences for daily or weekly
bisphosphonate therapy have been evaluated in prospective,
open-label studies [11, 12]. Actually, numerous studies have
proven that weekly dosing improves therapeutic adherence,
though it remains suboptimal [13–15].
Ibandronate is a potent, new aminobisphosphonate with
proven antifracture efficacy [2] and can be administered as
a monthly regimen. A comparative study (Monthly Oral
Iandronate in Ladies study [MOBILE]) demonstrated that
monthly ibandronate was as effective and well tolerated as
the currently approved daily ibandronate regimen in post-
menopausal osteoporosis [6]. Furthermore, two random-
ized, multicenter clinical trials (the Bonviva Alendronate
Trial in Osteoporosis [BALTO I and II]) found that sig-
nificantly more women with postmenopausal osteoporosis
preferred the monthly oral ibandronate regimen than the
weekly alendronate regimen [16, 17]. However, it is diffi-
cult to apply this result in Asian countries because both
studies had populations that were only about 1% Asian.
Moreover, there has been no randomized multicenter
clinical trial comparing patient preference between
ibandronate and risedronate, which is also widely pre-
scribed for the treatment of osteoporosis. In addition, there
were few studies comparing bone turnover markers
between ibandronate and risedronate.
This study was aimed at determining whether the pref-
erence results of Caucasians are similar to those of Kore-
ans. Other objectives were comparison of preference,
convenience, and bone turnover marker between monthly
ibandronate and weekly risedronate.
Methods
Study Design
This was a 6-month, prospective, randomized, open-label,
multicenter, two-period, and two-sequence crossover study
to investigate patient preference on dosing between once-
monthly ibandronate and once-weekly risedronate. The
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study design was similar to that used in previous studies
(BALTO I and II) [16, 17] except that this study compared
ibandronate with risedronate, not alendronate, and mea-
sured serum C-telopeptide of type I collagen (CTX) of
participants both at baseline and 12 weeks after treatment
to examine the change in bone turnover.
The study was conducted between March 2007 and May
2008 in 15 centers in South Korea and enrolled ambulatory
women with postmenopausal osteoporosis who were bis-
phosphonate-naive. Participants were required to be able to
understand and complete the Preference Questionnaire and
to comply with the study protocol to be enrolled in this
study. Women with upper GI disease such as reflux
esophagitis uncontrolled with drugs or delayed esophageal
emptying or active gastric/duodenal ulcer and who were
unable to maintain an upright position for at least
60 minutes were excluded. Subjects who had hypersensi-
tivity to ibandronate or risedronate; any other metabolic
bone diseases but postmenopausal osteoporosis; any
chronic diseases which could affect bone metabolism; or
any abnormalities in laboratory parameters such as serum
calcium, liver, or kidney function test and had been taking
glucocorticoid were also excluded. All participants pro-
vided informed consent. The appropriate independent eth-
ics committee or institutional review board approved the
study protocol and all materials provided to participants.
After a 30-day screening period, eligible participants
were randomized to take either monthly oral ibandronate
150 mg (Bonviva; F. Hoffmann-La Roche Ltd, Basel,
Switzerland) for 3 months followed by weekly oral
risedronate 35 mg (Actonel; Sanofi-Aventis Korea, Seoul,
Korea) for 12 weeks (sequence A) or the same regimen in
reverse order (sequence B) (Fig. 1). Central randomization
was used to ensure similar distribution between the two
sequences. There was no washout period between the two
treatment regimens. The crossover in treatment regimens
occurred after 3 months’ treatment with ibandronate
(sequence A) or 12 weeks’ treatment with risedronate
(sequence B). Additional safety information was collected
15 days after the end of treatment. Participants were edu-
cated to take both study medications in the morning after
an overnight fast (6 hours or more), to keep an upright
position (sitting or standing), and not to eat or drink fluids
other than water for either 60 minutes or 30 minutes after
taking ibandronate or risedronate, respectively. All partic-
ipants received appropriate dosing and administration
instructions and were reminded by telephone contact
before each medication dosing schedule (ibandronate every
month, risedronate every week). All women were supple-
mented with daily elemental calcium 500 mg and vitamin
D 125 IU (Oscal 500 D; Handok Pharmaceuticals, Seoul,
Korea). Compliance was estimated by recording drugs
dispensed versus drugs returned on the case record form.
Adverse events and laboratory parameters were assessed by
the study investigators. The use of clinically relevant
concomitant medications was also recorded.
The primary end point of this study was patients’ pref-
erence. The secondary end points were convenience and
bone turnover marker level.
Preference Questionnaire
All participants were asked to answer the Preference
Questionnaire at the end of the study (month 6) or when
Fig. 1 Study design and
randomization schedule
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they withdrew from the study. The Preference Question-
naire was adapted from the BALTO I and II [16, 17]. If
patients withdrew from the study before the crossover
point, i.e., after having taken only the first treatment in the
sequence, they were not requested to complete the ques-
tionnaire. If they withdrew after taking at least one dose of
the second treatment in the sequence, they were asked to
complete the questionnaire at the time of withdrawal.
Patients were asked to complete the questionnaire by
themselves before any other scheduled procedure at the
visit and were not assisted in completing the questionnaire.
Bone Turnover Marker
Serum levels of CTX were measured at baseline and after
3 months of treatment. Blood samples for CTX assess-
ments were taken at the end of the dosing interval (1 month
after 3-month dosing of ibandronate, one week after
12-week dosing of risedronate), after an overnight fast of at
least 6 hours, between 8:00 a.m. and 10:00 a.m., and pro-
cessed at the central laboratory (Green Cross Reference
Lab, Seoul, Korea). CTX levels were measured by elec-
trochemiluminescence immunoassay (Modular Analytics,
E170 Modular; Roche, Mannheim, Germany).
Statistical Analysis
The significance of preference and convenience was
assessed, accounting for the potential effect of treatment
order, using Gart’s test [18] (excluding subjects with no
preference) and Prescott’s test [19] (including all prefer-
ence and no preference data). Baseline and 3-month serum
CTX levels between the two groups were analyzed with
Student’s t-test. The mean percentage changes in serum
Fig. 2 Disposition of subjects
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CTX (3 months – baseline values) between the two
sequences were tested with ANCOVA and 95% confidence
interval. All the tests were two-sided, with a significance
level of P \ 0.05.
Results
Patient Disposition and Baseline Characteristics
A total of 365 women were enrolled in this study; 182 were
randomized to sequence A and 183 to sequence B. The
safety population (defined as patients who had received at
least one dose of trial medication and had follow-up data
end point) comprised 352 women included in the modified
intention-to-treat population (Fig. 2).
Participants in sequence A and sequence B were well
matched for age as well as weight, height, time since
menopause, and time since diagnosis of postmenopausal
osteoporosis (Table 1). There were no significant differ-
ences between sequences A and B in prior fragility frac-
ture, family history of fragility fracture in a first-degree
relative, and current smoking. The most common medica-
tions received by patients prior to study enrollment for the
treatment of osteoporosis were estrogen and progestin
(sequence A 34.5%, sequence B 34.7%).
Preference
Most women (262/314, 83.4%) preferred one of the two
regimens to the other. Of the patients who reported a pref-
erence, 74.8% (196/262) preferred the monthly regimen of
ibandronate and 25.2% (66/262) preferred the weekly regi-
men of risedronate. The preference rate for monthly
ibandronate was statistically significant (P \ 0.0001).
Preference for monthly ibandronate was not affected by the
order in which the women took the study medications (Gart
order-effect P = 0.6210). When data from all patients were
included, i.e., including women who did not express a
preference, 62.4% (196/314) preferred monthly ibandronate
dosing and 21.0% (66/314) preferred weekly risedronate
dosing (Fig. 3). Again, the preference rate for monthly
ibandronate was statistically significant (P\0.0001).
The reasons identified by patients for their preference are
detailed in Fig. 4 (patients could choose more than one rea-
son). Of the 74.8% of participants who expressed a prefer-
ence for the monthly ibandronate regimen, 77.6% (152/196)
chose the greater ease of long-term adherence and 52.6%
(103/196) a better lifestyle fit as a reason for their preference.
The proportions of participants who mentioned less stomach
discomfort and more easily tolerated side effects were 24.0%
(47/196) and 22.0% (43/196), respectively.
Convenience
Of the women expressing an opinion on convenience (229/
314, 72.9%), 84.2% found that the monthly ibandronate
regimen was more convenient and 15.8% (43/272) found
that the weekly risedronate regimen was more convenient.
The convenience rate for monthly ibandronate dosing was
statistically significant (P\0.0001). This opinion was not
Table 1 Patient demographics (safety population)
Variable Sequence A
(n = 176)
Sequence B
(n = 176)
Total
(n = 352)
Age (years)
Mean 61.3 62.0 61.7
Range 48–79 46–78 46–79
Height (cm)
Mean 154.3 154.6 154.5
Range 143–174 141–170 141–174
Weight (kg)
Mean 55.5 55.9 55.7
Range 37–76 36–81 36–81
Highest educational level
Elementary
school
47 (26.7%) 51 (29.0%) 98 (27.8%)
Middle/high
school
96 (54.6%) 73 (41.5%) 169 (48.0%)
College/
university
10 (5.7%) 17 (9.7%) 27 (7.7%)
Postgraduate
degree
0 (0.0%) 1 (0.6%) 1 (0.3%)
Unknown 23 (13.1%) 34 (19.3%) 57 (16.2%)
Current occupation
Working 31 (17.6%) 27 (15.3%) 58 (16.5%)
Not working 145 (82.4%) 149 (84.7%) 294 (83.5%)
Fracture history
Yes 37 (21.0%) 34 (19.3%) 71 (20.2%)
Sequence A: monthly ibandronate ? weekly risedronate
Sequence B: weekly risedronate ? monthly ibandronate
Fig. 3 Patient preferences for ibandronate monthly dosing over
risedronate weekly dosing, including patients who did not express a
preference for one treatment
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affected by treatment sequence (Gart order-effect, P =
0.8814). Similar results were shown when the analysis
included patients who did not express an opinion about
treatment convenience (Fig. 5): The monthly ibandronate
regimen was chosen by 72.9% of the overall study popu-
lation and the weekly risedronate regimen was chosen by
13.7%. Again, the convenience rate for monthly ibandro-
nate was statistically significant (P \ 0.0001).
Compliance
The compliance rate of the monthly ibandronate group was
significantly higher than that of the weekly risedronate
group (P \ 0.01). The difference in compliance was rela-
tively prominent at month 6 compared to month 3 (Table 2).
Bone Turnover Marker
There was no statistically significant difference between
the monthly and weekly bisphosphonate groups in baseline
and 3-month serum CTX levels. In addition, there was no
statistical significant difference between the two treatment
groups in mean percent change of serum CTX values
(Table 3).
Safety
The incidence of adverse events was comparable between
the two bisphosphonate regimens, with 41.0% and 40.1%
of patients experiencing at least one event during ibandr-
onate and risedronate treatment, respectively. Treatment-
related adverse events were reported by 29.5% of patients
during ibandronate treatment and 29.9% of patients during
risedronate treatment. Treatment-related GI adverse events
were reported by 19.4% of patients while taking ibandro-
nate and 23.1% of patients while taking risedronate. More
patients receiving once-weekly risedronate experienced
abdominal distension and nausea (6.9% vs. 3.3% and 6.9%
vs. 3.0%, respectively; P \ 0.05). Other frequent adverse
events were generally comparable between patients
receiving ibandronate and risedronate (Table 4). The inci-
dence of adverse events resulting in withdrawal from the
study was 4.2% (n = 14) in patients receiving ibandronate
and 4.5% (n = 15) in patients receiving risedronate.
Clinically relevant changes in laboratory parameters were
not observed in any patient during the study.
Discussion
Although bisphosphonates are regarded as the treatment of
choice for postmenopausal osteoporosis, their poor adher-
ence and persistence have limited their efficacy. It was
known that patients preferred less frequent, simpler, and
more convenient dosing regimens [20, 21]. A weekly
Fig. 4 Patient preferences and
reasons for preference
(excluding patients who did not
state a preference for one
treatment). Patients could
provide more than one reason
for preferring a particular
regimen
Fig. 5 Patients who found ibandronate monthly dosing more conve-
nient than risedronate weekly dosing, including patients who did not
express an opinion about convenience for one treatment
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dosing regimen has better therapeutic adherence than a
daily dosing regimen in postmenopausal osteoporosis;
however, it remains suboptimal [13–15]. Ibandronate is a
potent, nitrogen-containing bisphosphonate which has been
approved in Europe, the United States, and Korea to be
given as a monthly regimen. The BALTO I and II studies
reported that more women with postmenopausal osteopo-
rosis preferred the monthly ibandronate regimen and
expressed that the monthly ibandronate was more conve-
nient than the weekly alendronate regimen [16, 17].
However, these findings cannot be applied in Asian coun-
tries because the participants in these studies included only
about 1% Asian ethnicity. Furthermore, there have been
few studies about preferences between monthly ibandro-
nate and weekly risedronate, which have comparable effi-
cacy and tolerability in treatment of osteoporosis [22–24].
This study has not only reconfirmed previous findings from
the BALTO studies in Korea, an Asian country, but also
proved that monthly ibandronate had better preference and
convenience than weekly risedronate, similar to Western
results, which was highly expected despite the different
ethnicity.
One of the main reasons for noncompliance is the
occurrence of adverse events [25]. In this study, the overall
incidence of adverse events was similar between the two
bisphosphonate regimens. The number of patients who
were withdrawn from the study because of adverse events
was also similar in both treatments. These results were also
consistent with the previous BALTO studies.
Clinical trials evaluating the GI tolerability of bispho-
sphonates have found no significant differences in the
incidence of spontaneously reported GI adverse events
between placebo and bisphosphonates [2, 4, 26]. However,
GI adverse symptoms have been reported with bispho-
sphonate use in the clinical setting and may be an impor-
tant factor for discontinuing treatment [27–30]. BALTO I
and II reported that the patients receiving both the monthly
ibandronate and weekly alendronate regimens experienced
similar GI adverse events. In this study, more patients
receiving once-weekly risedronate experienced abdominal
distension and nausea, though other GI adverse events
occurred similarly in both treatments.
Table 2 Compliance with
study medication
Ibandronate n (%) Risedronate n (%) Total n (%) P (exact test)
Month 3
0–\50% 3 (1.9) 1 (0.6) 4 (1.3) 0.0018
50–\100% 1 (0.6) 12 (7.7) 13 (4.1)
100% 153 (97.5) 144 (91.7) 297 (94.6)
Total 157 (50.0) 157 (50.0) 314 (100.0)
Month 6
0–\50% 1 (0.6) 3 (1.9) 4 (1.3) \0.0001
50–\100% 1 (0.6) 19 (12.1) 20 (6.4)
100% 155 (98.7) 135 (86.0) 290 (92.3)
Total 157 (50.0) 157 (50.0) 314 (100.0)
Table 3 Changes in biochemical bone marker serum CTX
Serum CTX (ng/mL) Ibandronate Risedronate P (t-test)
Baseline
n 153 154
Mean ± SD 0.54 ± 0.26 0.50 ± 0.23 0.1861
Range 0.04–1.63 0.12–1.62
Month 3
n 153 155
Mean ± SD 0.21 ± 0.16 0.20 ± 0.15 0.4788
Range 0.02–0.97 0.03–0.70
Percent change
n 153 154
Mean ± SD –57.23 ± 35.89 –56.95 ± 37.07 0.9456
Range –96.28–172.41 –92.96–172.78
Table 4 Summary of most frequent adverse events (AE)
Ibandronate
(n = 336, %)
Risedronate
(n = 334, %)
P (v2 test)
Gastrointestinal AE 65 (19.4) 77 (23.1) 0.2402
Dyspepsia 25 (7.4) 24 (7.2) 0.8992
Abdominal distension 11 (3.3) 23 (6.9) 0.0332
Nausea 10 (3.0) 23 (6.9) 0.0194
Abdominal pain 10 (3.0) 5 (1.5) 0.1957
Abdominal pain upper 6 (1.8) 9 (2.7) 0.4266
Gastroesophageal reflux 7 (2.1) 7 (2.1) 0.9910
Musculoskeletal AE 63 (18.8) 50 (15.0) 0.1914
Myalgia 46 (13.7) 43 (12.9) 0.7556
Arthralgia 6 (1.8) 5 (1.5) 0.7687
Nervous system AE 17 (5.1) 18 (5.4) 0.8479
Headache 8 (2.4) 6 (1.8) 0.5969
Dizziness 7 (2.1) 5 (1.5) 0.5672
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In many clinical studies, monthly ibandronate showed a
significant increase in bone mineral density (BMD) and a
reduction in fracture risk [2, 6, 31]. Once-monthly iban-
dronate was shown to be clinically comparable to weekly
alendronate at increasing BMD after 12 months in both the
lumbar spine and total hip [32]. Furthermore, a retro-
spective cohort study found that patients treated with oral
monthly ibandronate or weekly bisphosphonates (alen-
dronate and risedronate) had similar low risks of hip
fracture, nonvertebral fracture, and any clinical fracture.
Ibandronate patients had a significantly lower relative risk
of vertebral fracture than weekly bisphosphonate patients
[33]. However, there were few studies comparing the
change in bone turnover marker after treatment with
monthly ibandronate and weekly bisphosphonates. In the
present study, although it was of relatively short duration,
both treatment regimens showed a similar percentage
change of bone turnover marker.
Recently, a study reported that the monthly ibandronate
regimen showed a better persistence rate with therapy than
the weekly regimen, even though telephone contact was
provided only to the monthly ibandronate group [34]. This
study was not designed to assess the persistence of treat-
ment. Further studies on monthly ibandronate persistence
will be required in Asian countries.
In conclusion, this study confirmed the patient prefer-
ence for monthly ibandronate over weekly bisphosphonates
in Korean. Moreover, the present study indicates that the
results previously reported vs. alendronate are also appli-
cable to risedronate. Monthly ibandronate showed similar
reduction of bone turnover marker compared to a weekly
regimen. Patients with a monthly ibandronate regimen
experienced fewer upper GI adverse events (nausea,
abdominal distension) in this study.
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